In an experimental back of the eye, autoimmune uveitis (EAU) model to be reported in a poster presentation at ARVO 2019, nomacopan (Coversin) and its long acting variants administered intravitreally, reported: ○ Significant improvement in clinical scoring versus control ○ Co-localization of LTB4
Treatment with Nomacopan (Coversin) in three patients with mild-to-moderate bullous pemphigoid (BP) resulted in no drug-related adverse events and rapid reduction in BP Disease Area Index (BPDAI) score and blistering in ongoing Phase II clinical trial Pivotal clinical trial for pediatric
Treatment with Nomacopan (Coversin) in three patients with mild-to-moderate bullous pemphigoid resulted in no drug-related adverse events and rapid reduction in Bullous Pemphigoid Disease Area Index (BPDAI) global score and blistering in ongoing Phase II clinical trial NEW YORK and LONDON, April
Poster to be presented on back-of-the-eye program including data from uveitis preclinical model Interim data expected from Akari’s Phase I/II clinical trial in atopic keratoconjunctivitis (AKC), a surface of the eye inflammatory disease NEW YORK and LONDON , March 27, 2019 (GLOBE NEWSWIRE) -- Akari
HSCT-TMA trial in pediatric patients expected to start Q4 2019 following recent FDA feedback NEW YORK and LONDON , March 13, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory
Planned introduction of patient-friendly pen auto-injector in 2019 designed to increase comfort and convenience of treatment across the entire Akari subcutaneous program Second eculizumab-resistant patient with paroxysmal nocturnal haemoglobinuria (PNH) successfully treated with Coversin for more
Highlights potential role of both complement and leukotriene pathways in a therapeutic mouse model of rheumatoid arthritis (RA) NEW YORK and LONDON , Nov. 15, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat
Four ongoing clinical trial programs Two clinical programs expected to report initial data in first quarter 2019 Long-term clinical study continues to yield encouraging safety data NEW YORK and LONDON , Nov. 15, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical
Coversin, a first-in-class combined complement C5 and leukotriene B4 (LTB4) inhibitor, is currently being developed to treat four orphan diseases: Thrombotic microangiopathies (TMAs) Bullous pemphigoid (BP) Atypical keratoconjunctivits (AKC) Paroxysmal nocturnal hemoglobinuriua (PNH) All four
